Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pcDNA3-sACE2-WT(732)-IgG1 Citations (7)

Originally described in: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, Herbert AS, Procko E Science. 2020 Sep 4;369(6508):1261-1265. doi: 10.1126/science.abc0870. Epub 2020 Aug 4.
PubMed Journal

Articles Citing pcDNA3-sACE2-WT(732)-IgG1

Articles
Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. Havranek B, Chan KK, Wu A, Procko E, Islam SM. J Chem Inf Model. 2021 Sep 27;61(9):4656-4669. doi: 10.1021/acs.jcim.1c00783. Epub 2021 Aug 24. PubMed
Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants. Zhang L, Dutta S, Xiong S, Chan M, Chan KK, Fan TM, Bailey KL, Lindeblad M, Cooper LM, Rong L, Gugliuzza AF, Shukla D, Procko E, Rehman J, Malik AB. bioRxiv. 2021 Dec 22. doi: 10.1101/2021.12.21.473668. PubMed
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Zhang L, Narayanan KK, Cooper L, Chan KK, Devlin CA, Aguhob A, Shirley K, Rong L, Rehman J, Malik AB, Procko E. bioRxiv. 2022 Mar 28. doi: 10.1101/2022.03.28.486075. PubMed
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. Zhang L, Narayanan KK, Cooper L, Chan KK, Skeeters SS, Devlin CA, Aguhob A, Shirley K, Rong L, Rehman J, Malik AB, Procko E. EMBO Mol Med. 2022 Nov 8;14(11):e16109. doi: 10.15252/emmm.202216109. Epub 2022 Sep 23. PubMed
Generation of SARS-CoV-2 Mouse Model by Transient Expression of the Human ACE2 Gene Mediated by Intranasal Administration of AAV-hACE2. Glazkova DV, Bogoslovskaya EV, Urusov FA, Kartashova NP, Glubokova EA, Gracheva AV, Faizuloev EB, Trunova GV, Khokhlova VA, Bezborodova OA, Pankratov AA, Leneva IA, Shipulin GA. Mol Biol. 2022;56(5):705-712. doi: 10.1134/S0026893322050065. Epub 2022 Oct 5. PubMed
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Cell. 2023 Jan 19;186(2):279-286.e8. doi: 10.1016/j.cell.2022.12.018. Epub 2022 Dec 14. PubMed
A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Havranek B, Lindsey GW, Higuchi Y, Itoh Y, Suzuki T, Okamoto T, Hoshino A, Procko E, Islam SM. Commun Biol. 2023 May 12;6(1):513. doi: 10.1038/s42003-023-04860-9. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.